Abbott Laboratories’ (ABT) stock price rose sharply on Thursday, gaining 10.61 percent. The increase came after the medical products provider raised its full-year profit forecast.
A savvy acquisition is driving Abbott’s growth. Abbott’s second-quarter sales rose 13 percent to $12.6 billion, benefiting from its $21 billion acquisition in March of Exact Sciences, a leader in cancer screening. The purchase added more preventive healthcare products to Abbott’s portfolio, including Exact Sciences’ market-leading non-invasive colorectal cancer screening test, Cologuard.
Abbott’s global diagnostics business saw sales surge 42.3 percent to $3.1 billion. At the same time, the healthcare giant’s global medical devices segment also posted steady revenue growth of 9 percent to $5.9 billion, driven largely by an 11 percent increase in sales of continuous glucose monitors. Overall, Abbott’s adjusted earnings rose 4 percent to $1.31 per share, beating Wall Street expectations of $1.28 per share.
Higher profits mean greater dividend returns for investors. Looking ahead, Abbott expects full-year 2026 comparable sales to grow between 6.5 percent and 7.5 percent. Management also raised its adjusted earnings per share outlook to between $5.45 and $5.60, up from the previous forecast of $5.38 to $5.58. Abbott’s strengthening profitability enables it to reward shareholders with steadily growing cash returns. The medical devices and testing leader has raised its dividend for 54 consecutive years.
Abbott is a diversified healthcare leader with businesses spanning medical devices, diagnostic tools, nutritional products and generic pharmaceuticals. Its product portfolio includes high-growth areas such as diabetes care and cardiovascular solutions. As of March 2026, the company expanded its oncology presence through the $23 billion acquisition of Exact Sciences. The deal integrated new cancer diagnostic technologies into the existing diagnostics products division. Abbott does not rely on any single customer for the majority of its revenue, which helps mitigate the risk of sudden business loss.
For fiscal year 2025, Abbott posted revenue of $44.3 billion, an increase of approximately 5.5 percent from the prior year. The company reported net income of nearly $6.5 billion for the same period, representing a net profit margin of 14.7 percent. Despite steady revenue growth, this net margin was below the 31.9 percent recorded in 2024, reflecting the cost impact of its large-scale business transformation and recent acquisitions. Its current debt-to-equity ratio stands at approximately 0.65 times. This ratio measures total debt relative to shareholders’ equity, with a lower ratio indicating less reliance on borrowed funds. Free cash flow for fiscal year 2025, which is the cash remaining after capital expenditures, was close to $7.4 billion.
In summary, Abbott’s recent stock price rally was primarily driven by better-than-expected second-quarter results and an upward revision to its full-year earnings forecast. Through the acquisition of Exact Sciences, Abbott has gained new growth momentum in its diagnostics business, with the addition of cancer screening products further enriching its product pipeline. At the same time, the solid performance of core businesses such as medical devices and continuous glucose monitors provided strong support for overall revenue. Although the large-scale acquisition and business adjustments exerted some pressure on the net profit margin in the short term, the company’s sustained dividend growth and healthy cash flow position demonstrate the resilience of its financial foundation. Abbott’s diversified business structure and revenue model that does not depend on a single customer also help reduce operational risks, providing a relatively stable foundation for its future growth.
